DYSLIPIDEMIA AND ATHEROSCLEROSIS SLIDE COLLECTION

Author:

JEAN-CHARLES FRUCHART

 




This is a collection of slides on dyslipidemia and its role in atherosclerosis, the most relevant and current data related to:

  • the epidemiology and pathophysiology of atherosclerosis,
  • the atherogenicity of lipids and lipoproteins,
  • the mismacht between our genotype and the Western lifestyle,
  • and the genetic mechanisms of action of lipid-modifying drugs in atherosclerosis

are presented.



DISCLAIMER

CONTACT US



 

KEYWORDS:

Summary:

Atherosclerosis: The global epidemic of modern living

Pathophysiology:

The stages of development of atherosclerosis
The role of the macrophage
The role of atherogenic lipoproteins
The influence of risk factors
The goals of treatment

Physiology of lipids and lipoproteins:

Synthesis and transport
Atherogenicity

Genotype and dyslipidemia: Genetic evolution can’t keep up with our lifestyle!

Genetic mechanisms of drug action:

Direct PPAR alpha activation (fibrates I)
Direct PPAR alpha activation (fibrates II)
Direct PPAR alpha activation (fibrates III)
SREBP feedback control (statins)
Indirect PPARalpha activation (statins)

Key clinical trials:

Fibrates (VA-HIT, DAIS, HHS)
Statins I (4S, CARE, WOSCOPS, LIPID)
Statins II (AFCAPS/TexCAPS, AVERT, HPS)

Guidelines:

NCEP
AHA/ACC
ADA
ILIB/IAS recommendations

Abbreviations list

References

 

This slides collection has been made possible by an unrestricted educational grant kindly offered by Fournier Pharma, France and made available to the International Atherosclerosis society (IAS) by Prof. Jean-Charles Fruchart.

BEST SEEN WITH MICROSOFT INTERNET EXPLORER 6 AND 1024X768 PIXELS SCREEN RESOLUTION